BioSpace News Archive

Iterion Therapeutics, Inc., a venture-backed, clinical-stage

Delic Holdings Corp today announced details regarding Matt Stang, co-founder and CEO of Delic, and his participation at the upcoming HC Wainwright Bioconnect Virtual Conference and CEM’s 8th annual AlphaNorth Capital Conference in January.

Inspirna, Inc. announced today the appointment of Josep Tabernero, M.D., Ph.D. and Alan P. Venook, M.D., to its scientific advisory board.

Atara Biotherapeutics, Inc. today announced new preclinical and preliminary clinical results for ATA2271, a next-generation autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin (MSLN).

Agendia Presents Data at SABCS 2021 Showing MammaPrint ® and BluePrint ® More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors.

Sesen Bio today announced its anticipated regulatory path forward for Vicineum™ or the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).

BlueCube Bio officially announced a company name transition to Evia Bio™, concurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs).

FSD Pharma Inc. announced today that it has formed a Regulatory Advisory Board (“RAB”) and has appointed Joga Gobburu, B.Pharm. (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members.

Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection.